Report cover image

Atezolizumab Market, By Drug Class (PD-L1 Inhibitors, PD-1 Inhibitors, CTLA-4 Inhibitors, Immunomodulators, and Others), By Indication (Lung Cancer, Bladder Cancer, Melanoma, Hodgkins Lymphoma, Head and Neck Cancer, and Others)), By Distribution Channel (

Publisher Coherent Market Insights
Published Mar 27, 2025
Length 160 Pages
SKU # CMI20008832

Description

Atezolizumab is a breakthrough immunotherapy drug that has revolutionized the treatment of multiple types of cancer. This therapeutic antibody, developed by Roche, inhibits the programmed death-ligand 1 (PD-L1) protein, which enables cancer cells to evade immune system detection. By blocking PD-L1, atezolizumab unleashes the power of the immune system to recognize and attack cancer cells, leading to improved patient outcomes.

Market Dynamics:

The market for atezolizumab is experiencing significant growth, driven by several key factors. Firstly, the rising incidence of cancer globally is increasing the demand for effective treatment options. Atezolizumab has shown promising results in various cancers, including lung, bladder, and breast cancer, thus expanding the addressable patient population. Additionally, the growing awareness about the benefits of immunotherapy and the preference for targeted therapies are further bolstering market growth.

However, despite the numerous opportunities, there are certain factors restraining the market. The high cost of atezolizumab is a major barrier, limiting access to patients in lower-income countries and even in some developed markets. Additionally, the complex and lengthy regulatory approval process for new drugs poses a challenge for market entry. Moreover, the emergence of alternative immunotherapy treatments and the availability of biosimilars could also hinder market growth.

Nevertheless, the market for atezolizumab holds immense potential for future development. The ongoing research and development efforts by key players such as Novartis, Pfizer, Merck, AstraZeneca, Bristol-Myers Squibb, BeiGene, Innovent Biologics, Genentech, and AbbVie are expected to yield innovative treatment options, expanding the market further. The increasing focus on precision medicine and the development of companion diagnostics are also creating opportunities for personalized treatment approaches using atezolizumab.

Key Features of the Study:
  • This report provides in-depth analysis of the global Atezolizumab market, including market size (US$ Billion) and compound annual growth rate (CAGR%) for the forecast period (2025–2032), with 2024 as the base year.
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players.
  • Key players in the global Atezolizumab market profiled in this study include Roche, Novartis, Pfizer, Merck, AstraZeneca, Bristol-Myers Squibb, BeiGene, Innovent Biologics, Genentech, and AbbVie.
  • Insights from this report would enable marketers and management authorities to make informed decisions regarding future product launches, upgrades, market expansion, and marketing tactics.
  • The global Atezolizumab market report caters to various stakeholders in the industry, including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
  • Stakeholders will have ease in decision-making through various strategy matrices used for analyzing the global Atezolizumab market.
Atezolizumab Market Segmentation:
  • By Drug Class:
  • PD-L1 Inhibitors
  • PD-1 Inhibitors
  • CTLA-4 Inhibitors
  • Immunomodulators
  • Others
  • By Indication:
  • Lung Cancer
  • Bladder Cancer
  • Melanoma
  • Hodgkin’s Lymphoma
  • Head and Neck Cancer
  • Others
  • By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • By Route of Administration:
  • Intravenous
  • Oral
  • Others
  • By End User:
  • Hospitals
  • Homecare
  • Specialty Clinics
  • Others
  • By Region:
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa
  • Company Profiles
  • Roche
  • Novartis
  • Pfizer
  • Merck
  • AstraZeneca
  • Bristol-Myers Squibb
  • BeiGene
  • Innovent Biologics
  • Genentech
  • AbbVie

Table of Contents

160 Pages
1. Research Objectives and Assumptions
Research Objectives
Assumptions
Abbreviations
2. Market Purview
Report Description
Market Definition and Scope
Executive Summary
Market Atezolizumab, By Drug Class
Market Atezolizumab, By Indication
Market Atezolizumab, By Distribution Channel
Market Atezolizumab, By End User
Market Atezolizumab, By Region
Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
Market Dynamics
Drivers
Rising incidence of cancer globally
Increasing demand for effective treatment options
Restraints
High cost of atezolizumab
Opportunities
Ongoing research and development efforts by key players
Impact Analysis
Key Highlights
Regulatory Scenario
Product launch/Approvals
PEST Analysis
PORTER’s Analysis
Merger and Acquisition Scenario
4. Global Atezolizumab Market – Impact of Coronavirus (COVID-19) Pandemic
COVID-19 Epidemiology
Supply Side and Demand Side Analysis
Economic Impact
5. Global Atezolizumab Market, By Drug Class, 2020-2032, (US$ Bn)
Introduction
Market Share Analysis, 2025 and 2032 (%)
Y-o-Y Growth Analysis, 2021 – 2032
Segment Trends
PD-L1 Inhibitors
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
PD-1 Inhibitors
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
CTLA-4 Inhibitors
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
Immunomodulators
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
Others
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
6. Global Atezolizumab Market, By Indication, 2020-2032, (US$ Bn)
Introduction
Market Share Analysis, 2023and 2032 (%)
Y-o-Y Growth Analysis, 2021– 2032
Segment Trends
Lung Cancer
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
Bladder Cancer
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
Melanoma
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
Hodgkin’s Lymphoma
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
Head and Neck Cancer
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
Others
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
7. Global Atezolizumab Market, By Distribution Channel, 2020-2032, (US$ Bn)
Introduction
Market Share Analysis, 2023and 2032 (%)
Y-o-Y Growth Analysis, 2021– 2032
Segment Trends
Hospital Pharmacies
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
Retail Pharmacies
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
Online Pharmacies
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
8. Global Atezolizumab Market, By End User, 2020-2032, (US$ Bn)
Introduction
Market Share Analysis, 2023and 2032 (%)
Y-o-Y Growth Analysis, 2021– 2032
Segment Trends
Hospitals
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
Homecare
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
Specialty Clinics
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
Others
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
9. Global Atezolizumab Market, By Region, 2020-2032, (US$ Bn)
Introduction
Market Share Analysis, By Country, 2023and 2032 (%)
Y-o-Y Growth Analysis, For Country 2021–2028
Country Trends
North America
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020-2032, (US$ Bn)
Market Size and Forecast, and Y-o-Y Growth, By Indication, 2020-2032, (US$ Bn)
Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (US$ Bn)
Market Size and Forecast, and Y-o-Y Growth, By End User, 2020-2032, (US$ Bn)
Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (US$ Bn)
Europe
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020-2032, (US$ Bn)
Market Size and Forecast, and Y-o-Y Growth, By Indication, 2020-2032, (US$ Bn)
Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (US$ Bn)
Market Size and Forecast, and Y-o-Y Growth, By End User, 2020-2032, (US$ Bn)
Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (US$ Bn)
Asia Pacific
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020-2032, (US$ Bn)
Market Size and Forecast, and Y-o-Y Growth, By Indication, 2020-2032, (US$ Bn)
Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (US$ Bn)
Market Size and Forecast, and Y-o-Y Growth, By End User, 2020-2032, (US$ Bn)
Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (US$ Bn)
Latin America
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020-2032, (US$ Bn)
Market Size and Forecast, and Y-o-Y Growth, By Indication, 2020-2032, (US$ Bn)
Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (US$ Bn)
Market Size and Forecast, and Y-o-Y Growth, By End User, 2020-2032, (US$ Bn)
Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (US$ Bn)
Middle East & Africa
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020-2032, (US$ Bn)
Market Size and Forecast, and Y-o-Y Growth, By Indication, 2020-2032, (US$ Bn)
Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (US$ Bn)
Market Size and Forecast, and Y-o-Y Growth, By End User, 2020-2032, (US$ Bn)
Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (US$ Bn)
10. Competitive Landscape
Roche
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
Novartis
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Strategies
Pfizer
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Strategies
Merck
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Strategies
AstraZeneca
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Strategies
Bristol-Myers Squibb
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Strategies
BeiGene
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Strategies
Innovent Biologics
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Strategies
Genentech
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Strategies
AbbVie
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Strategies
Analyst Views
11. Section
Research Methodology
About us
*Browse 24 market data tables and 28 figures on Global Atezolizumab Market” - Global forecast to 2032

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us